Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.
Please consider a small donation if you think this website provides you with relevant information
| Date | Title | Source |
|---|---|---|
| 2024-03-11 1:6:35 pm | Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia | GlobeNewsWire |
| 2024-03-06 1:5:0 pm | Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference | GlobeNewswire |
| 2024-02-16 1:20:0 pm | Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares | GlobeNewswire |
| 2024-02-14 3:15:0 am | Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock | GlobeNewswire |
| 2024-02-13 1:18:0 pm | Larimar Therapeutics Announces Proposed Underwritten Public Offering | GlobeNewswire |
| 2024-02-12 4:0:0 am | Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia | GlobeNewswire |
Please consider a small donation if you think this website provides you with relevant information